• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Index Ventures launches $198 million life sciences fund

Index Ventures launches $198 million life sciences fund

March 21, 2012
CenterWatch Staff

Index Ventures, a venture capital firm, has launched its first fund solely dedicated to making investments in the life sciences sector.

The fund, amounting to $198 million, includes investments from several of Index's largest existing limited partners and two companies, GlaxoSmithKline (GSK) and the venture capital affiliate of the Janssen pharmaceutical companies of Johnson & Johnson. 

With this investment in the fund, the two global pharmaceutical companies will share their expertise by participating in the fund’s scientific advisory board. Index will maintain full decision making rights to the portfolio companies and the fund rules and procedures will follow previous Index Ventures funds. This pharma/venture partnership model is intended to stimulate promising, early-stage R&D innovation. 

Index's "asset centric" model focuses on investment in companies with just one or two projects, rather than companies with multiple programs. The fund will primarily consider opportunities across Europe, but also in the U.S., with assets that have first-in-class or best-in-class mechanisms of action and target areas of unmet medical need.  

"New and creative approaches to funding early stage innovation are crucial to the development of transformative medicine,” said Dr. Paul Stoffels, worldwide chairman, pharmaceuticals group, Johnson & Johnson. “We believe that supporting and nurturing start-ups and encouraging entrepreneurship and innovation will be good for the entire industry." 

The fund’s scientific advisory board will be composed of nine members: Dr. Moncef Slaoui and Dr. Paul-Peter Tak from GSK; Stoffels and Dr. Bill Hait from Janssen; and five Index Ventures-appointed executives: Francesco De Rubertis, Kevin Johnson, Michele Ollier, Roman Fleck and Remy Luthringer.  

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing